A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED)

NCT00605033 | Completed Phase 4 Results

• 2 other identifiers: P04843SWITCH
• Study Type: interventional
• Target: 241
• Locations: 0 countries
• Sites: N/A

Brief Summary

Post-marketing commitment to the European Medicines Agency to conduct a prospective, controlled study of the transfer from Subutex to Suboxone.

Conditions

Opiate Dependence; Drug Dependence

Outcome Measures

Primary Outcomes (1)

• Response Rate

  Response rate was defined as the percentage of participants who did not receive a dose increase from the dose given at the first dosing date by Day 7 of a one-week, randomized, double-blind, double-dummy treatment transfer phase.

  Assessed by Day 7 of double-blind, double-dummy treatment period.

Study Arms (2)

Suboxone

ACTIVE COMPARATOR

Double-blind, once-daily sublingual Suboxone (buprenorphine/naloxone 4 mg/1 mg to 24 mg/6 mg) plus matching Subutex placebo during Week 1 followed by open-label, once-daily sublingual Suboxone (buprenorphine/naloxone 4 mg/1 mg to 24 mg/6 mg) during Weeks 2-4 with weekly access to take-home doses as of Week 2.

Drug: Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484

Subutex

ACTIVE COMPARATOR

Double-blind, once-daily sublingual Subutex (buprenorphine 4 mg to 24 mg) plus matching Suboxone placebo during Week 1 followed by open-label, once-daily sublingual Subutex (buprenorphine 4 mg to 24 mg) during Weeks 2-4 with weekly access to take-home doses as of Week 2.

Drug: Subutex, Buprenorphine Hydrochloride, SCH 28444

Interventions

Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484 DRUG

Suboxone sublingual tablet 4 mg/1 mg - 24 mg/6 mg, daily for 28 days

Suboxone

Subutex, Buprenorphine Hydrochloride, SCH 28444 DRUG

Subutex sublingual tablet 4-24 mg, daily for 28 days

Subutex

Eligibility Criteria

• Age: 15 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects must be males or non-pregnant, non-lactating females.
• Subjects must be at least 15 years of age, of either sex, and any race.
• Subjects (and/or the parent or guardian for subjects under the age of legal consent or who otherwise are unable to provide independent consent) must demonstrate willingness to participate in the study and to adhere to dose and visit schedules.
• Subjects must meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria(18) for opioid dependence.
• Subjects must have been receiving maintenance treatment with Subutex at doses ranging from 4 mg to the maximum dose permitted by country labeling requirements, but not to exceed 24 mg/day, for at least 1 month prior to screening.
• Subjects must not, according to self-report, have injected opioids more than four times in the month prior to screening.
• Subjects must have an opioid-negative urine drug screening (UDS) result prior to randomization.
• Each subject must confirm that he or she is practicing adequate contraception.
• Female subjects of childbearing potential must have a negative urine beta-human chorionic gonadotropin (β-hCG) test prior to enrollment in the study.

You may not qualify if:

• Subjects for whom treatment with either Subutex or Suboxone as required in the protocol would be inconsistent with national labeling.
• Subjects who are unwilling or unable to comply with the requirements of the protocol (eg, pending incarceration) or are in a situation or condition that, in the opinion of the investigator, may interfere with participation in the study.
• Subjects who are participating in any other clinical study in which medication(s) are being delivered.
• Subjects with known allergy or sensitivity to naloxone.
• Subjects who are on the staff, affiliated with, or a family member of the staff personnel directly involved with this study.
• Subjects must not have serious untreated Axis I DSM-IV-TR psychiatric comorbidity (eg, those who are actively suicidal or homicidal, have untreated schizophrenia, etc). Polysubstance abuse or dependence will not exclude subjects except in the case of unauthorized and significant benzodiazepine use requiring medical detoxification or alcohol dependence requiring medical detoxification.
• Human immunodeficiency virus (HIV)-positive subjects with clinical acquired immunodeficiency syndrome (AIDS).
• Subjects treated with generic buprenorphine.

Sponsors & Collaborators

• Indivior Inc.: lead

MeSH Terms

Conditions

Opioid-Related Disorders; Substance-Related Disorders

Interventions

Buprenorphine, Naloxone Drug Combination; Buprenorphine; Naloxone

Condition Hierarchy (Ancestors)

Narcotic-Related Disorders; Chemically-Induced Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Morphinans; Opiate Alkaloids; Alkaloids; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, 4 or More Rings; Heterocyclic Compounds, Fused-Ring; Phenanthrenes; Polycyclic Aromatic Hydrocarbons; Polycyclic Compounds; Drug Combinations; Pharmaceutical Preparations

Results Point of Contact

• Title: Head, Clinical Trials Registry & Results Disclosure Group
• Organization: Schering-Plough

ClinicalTrialsDisclosure@spcorp.com

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 17, 2008
• First Posted: January 30, 2008
• Study Start: March 1, 2008
• Primary Completion: April 1, 2009
• Study Completion: May 1, 2009
• Last Updated: October 21, 2016
• Results First Posted: June 30, 2010

Record last verified: 2016-09